{"id":843223,"date":"2026-10-22T11:28:01","date_gmt":"2026-10-22T11:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=843223"},"modified":"2026-10-22T11:28:01","modified_gmt":"2026-10-22T11:28:01","slug":"watch-now-vivs-igc-xxii-and-shfs-low-price-listed-stocks-in-focus","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/watch-now-vivs-igc-xxii-and-shfs-low-price-listed-stocks-in-focus_843223.html","title":{"rendered":"Watch Now: VIVS, IGC, XXII and SHFS Low Price Listed Stocks in Focus"},"content":{"rendered":"
\"Watch<\/a><\/div>\n

Four low-priced listed stocks bring drug-testing technology, Alzheimer’s AI, rising retail sales and a new compliance deadline into focus.<\/strong><\/p>\n

DALLAS, Texas, October 22, 2026<\/strong> – VivoSim Labs (NASDAQ: VIVS), IGC Pharma (NYSE American: IGC), 22nd Century Group (NASDAQ: XXII) and SHF Holdings (NASDAQ: SHFS)<\/strong> are drawing attention to developments spanning healthcare technology, tobacco retailing and financial services.<\/p>\n

VivoSim Labs: Human Tissue Models Target Drug-Testing Applications<\/strong><\/p>\n

VivoSim Labs, Inc. (NASDAQ: VIVS)<\/strong> is advancing its NAMkind™ 3D human tissue models and VitroSense™ AI predictive toxicology platform<\/strong> as pharmaceutical developers evaluate alternatives to animal testing.<\/p>\n

The company reported 91% predictive accuracy, 90% sensitivity and 95% specificity<\/strong> for its liver model across a 92-compound dataset. VitroSense™ separately reported up to 96% predictive accuracy<\/strong> for potential drug-induced diarrhea.<\/p>\n

A developing rat liver model aims to help assess whether animal toxicity findings translate to humans. Validation, pharmaceutical adoption and potential regulatory submissions remain milestones to watch; NAMkind™ has not been announced as FDA-qualified.<\/p>\n

IGC Pharma: PRISM Expands Alzheimer’s AI Commercialization Strategy<\/strong><\/p>\n

IGC Pharma, Inc. (NYSE American: IGC)<\/strong> introduced PRISM<\/strong>, an application layer connecting its patent-pending MINT-AD Alzheimer’s AI platform<\/strong> with potential healthcare applications.<\/p>\n

PRISM targets risk stratification, cognitive monitoring, clinical-trial optimization and personalized brain-health programs. IGC is evaluating B2B, B2B2C and online commercialization opportunities<\/strong> serving providers, memory clinics, pharmaceutical companies and consumer platforms. Validation and deployment agreements will help measure progress toward commercial use.<\/p>\n

22nd Century Group: Pinnacle Retail Unit Sales Rise 161% Sequentially<\/strong><\/p>\n

22nd Century Group, Inc. (NASDAQ: XXII)<\/strong> reported that combined same-store retail unit sales of Pinnacle VLN® and Pinnacle Pure increased 161% from the second to third quarter<\/strong> at its launch retail partner, which operates approximately 1,500 outlets.<\/p>\n

Management attributed the increase partly to consumer awareness and promotional activity. Pinnacle VLN® offers low-nicotine cigarettes, while Pinnacle Pure expands the portfolio with a tobacco-and-water formulation. The reported increase measures unit sales at that partner, rather than company-wide revenue growth.<\/p>\n

SHF Holdings: Nasdaq Extension Establishes April 2027 Deadline<\/strong><\/p>\n

SHF Holdings, Inc. (NASDAQ: SHFS), doing business as Safe Harbor Financial<\/strong>, announced on October 20, 2026<\/strong>, an additional 180-day Nasdaq compliance period<\/strong>, extending its minimum-bid-price deadline to April 19, 2027<\/strong>. Its shares remain listed on The Nasdaq Capital Market.<\/p>\n

Safe Harbor provides banking, lending, payments and business services through financial institution partners. The company reports assisting with more than $36 billion in depository funds across 41 states and territories<\/strong>. Business expansion and progress toward restoring bid-price compliance remain developments to monitor.<\/p>\n

About the Companies<\/strong><\/p>\n

VivoSim develops tissue-based drug-testing tools. IGC Pharma advances Alzheimer’s therapeutics and AI healthcare technologies. 22nd Century develops tobacco products, including low-nicotine cigarettes. Safe Harbor Financial provides financial services and banking support.<\/p>\n

About The Street Reports<\/strong><\/p>\n

The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.<\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Four low-priced listed stocks bring drug-testing technology, Alzheimer’s AI, rising retail sales and a new compliance deadline into focus. DALLAS, Texas, October 22, 2026 – VivoSim Labs (NASDAQ: VIVS), IGC Pharma (NYSE American: IGC), 22nd Century Group (NASDAQ: XXII) and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,412,406,411],"tags":[],"class_list":["post-843223","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/843223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=843223"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/843223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=843223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=843223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=843223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}